Clinical Trial Detail

NCT ID NCT01829971
Title A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements no
Sponsors Mirna Therapeutics, Inc.
Indications

liver cancer

chronic myeloid leukemia

lymphoma

Advanced Solid Tumor

myelodysplastic/myeloproliferative neoplasm

chronic lymphocytic leukemia

acute lymphocytic leukemia

multiple myeloma

Therapies

MRX34

Age Groups: adult senior

No variant requirements are available.